Welcome to our dedicated page for ALBO news (Ticker: ALBO), a resource for investors and traders seeking the latest updates and insights on ALBO stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ALBO's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ALBO's position in the market.
Albireo Pharma (Nasdaq: ALBO) presented new data from the Phase 3 PEDFIC 1 and PEDFIC 2 trials at the ESPGHAN annual meeting in Copenhagen. These studies, the largest in progressive familial intrahepatic cholestasis (PFIC), demonstrated that dose escalation of Bylvay (odevixibat) significantly improves pruritus response and related quality-of-life measures, including sleep, in pediatric patients. Long-term treatment data indicate sustained benefits across all PFIC types over 72 weeks.
Albireo Pharma (ALBO) presented new data on Bylvay (odevixibat) during the EASL International Liver Congress 2022, highlighting the drug's efficacy in treating progressive familial intrahepatic cholestasis (PFIC). Analyses from Phase 3 PEDFIC trials demonstrated that patients experiencing pruritus relief with Bylvay also showed improvements in sleep, quality of life, serum bile acids, and hepatic parameters. Moreover, Albireo launched the SPARK Grants Program to enhance care for rare liver diseases, starting with PFIC, encouraging innovative projects from healthcare professionals.
Albireo Pharma (Nasdaq: ALBO) announced the acceptance of five abstracts for presentation at the EASL International Liver Congress 2022, showcasing long-term data from its Phase 3 studies of Bylvay™ (odevixibat) in children with progressive familial intrahepatic cholestasis (PFIC). The data confirms durable efficacy, highlighting improvements in quality of life, growth, sleep, and hepatic biomarkers. Additionally, two abstracts focus on early-stage assets for treating adult cholestatic and viral liver diseases. The Congress will be held from June 22-26, 2022, in London.
Albireo Pharma (Nasdaq: ALBO) announced the acceptance of four abstracts featuring Phase 3 data from its PEDFIC 1 and PEDFIC 2 trials of Bylvay™ (odevixibat) at the ESPGHAN conference in Copenhagen, scheduled for June 22-25, 2022. The presentations will cover crucial aspects such as long-term safety, tolerability, and improvements in quality of life in children with progressive familial intrahepatic cholestasis (PFIC). A symposium will also be held to discuss real-life treatment experiences with an IBAT inhibitor.
Albireo Pharma, Inc. (Nasdaq: ALBO) announced that CEO Ron Cooper will present at two upcoming investor conferences: the William Blair 42nd Annual Growth Stock Conference on June 7 at 9:00 a.m. ET, and the Jefferies Healthcare Conference on June 8 at 10:00 a.m. ET. Webcasts of the presentations will be available on Albireo's Investors page for on-demand viewing. Albireo focuses on developing novel bile acid modulators for treating rare liver diseases, with its lead product, Bylvay, approved for pruritus in progressive familial intrahepatic cholestasis.
Albireo Pharma (ALBO) presented six abstracts at the Digestive Disease Week Annual Meeting, highlighting data on Bylvay (odevixibat) for treating pruritus in progressive familial intrahepatic cholestasis (PFIC). The studies demonstrated Bylvay's efficacy in managing pruritus and lowering serum bile acids. Additionally, a preclinical study indicated potential for dual-acting bile acid modulators targeting cholestatic liver diseases. Bylvay is approved for PFIC treatment in the U.S. for patients aged 3 months and older, and in Europe for those aged 6 months and older, with ongoing trials for related conditions.
BOSTON, May 19, 2022 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO) announced its participation in the H.C. Wainwright Global Life Science Conference from May 23-26, 2022. CFO Simon Harford will present on May 25, with an on-demand option available on the Albireo Investors page. Additionally, both Simon and Chief Commercial Officer Pamela Stephenson will conduct investor meetings.
Albireo focuses on developing bile acid modulators for rare liver diseases. Its lead product, Bylvay, is FDA-approved for pruritus in progressive familial intrahepatic cholestasis and undergoing trials for other conditions.
Albireo Pharma (ALBO) announced a successful global launch of Bylvay, generating $4.7 million in Q1 2022 product revenue. Strong patient uptake reflects a 64% growth from Q4 2021, with 87 reimbursed patients by the end of Q1. The Phase 3 ASSERT study in Alagille syndrome is fully enrolled, with topline data expected in 2022. The company maintains strong U.S. payer coverage and is preparing for European market launches. Financial results indicate a net loss of $42.4 million for Q1 2022, with cash reserves of $216.7 million anticipated to last into 2024.
Albireo Pharma (ALBO) will host a conference call on May 16, 2022, at 4:30 PM ET to discuss its Q1 2022 financial results and provide a business update. The call can be accessed by phone or through a live audio webcast on the company's Investor page. Albireo focuses on developing novel bile acid modulators for rare liver diseases, with its lead product, Bylvay, FDA-approved for treating pruritus in progressive familial intrahepatic cholestasis. Bylvay is also undergoing further development for other pediatric liver diseases.
Albireo Pharma (ALBO) has completed patient enrollment in the Phase 3 ASSERT study for Bylvay (odevixibat) in Alagille syndrome, surpassing the initial target of 45 participants with a total of 52. Topline data is expected by year-end 2022. The ASSERT trial is a critical, global study focusing on Bylvay’s efficacy and safety, with US FDA and EMA approval on the study design. Additionally, an Expanded Access Program has been launched to provide Bylvay to patients with ALGS ahead of its formal approval.
